Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

Amulya Yellala; Apar Kishor Ganti

doi:10.21037/tlcr.2020.04.12

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	824-827
Number of pages	4
Journal	Translational Lung Cancer Research
Volume	9
Issue number	3
DOIs	https://doi.org/10.21037/tlcr.2020.04.12
State	Published - Jun 1 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.21037/tlcr.2020.04.12

Cite this

@article{118251b345984a0ab5079e6d822e8255,

title = "Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)",

author = "Amulya Yellala and Ganti, {Apar Kishor}",

year = "2020",

month = jun,

day = "1",

doi = "10.21037/tlcr.2020.04.12",

language = "English (US)",

volume = "9",

pages = "824--827",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

number = "3",

}

TY - JOUR

T1 - Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

AU - Yellala, Amulya

AU - Ganti, Apar Kishor

PY - 2020/6/1

Y1 - 2020/6/1

UR - http://www.scopus.com/inward/record.url?scp=85090183764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090183764&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2020.04.12

DO - 10.21037/tlcr.2020.04.12

M3 - Comment/debate

C2 - 32676346

AN - SCOPUS:85090183764

SN - 2218-6751

VL - 9

SP - 824

EP - 827

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 3

ER -

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this